RecruitingEarly Phase 1NCT06412952

68Ga-NOTA-RM26 PET/CT in Glioma Patients


Sponsor

Peking Union Medical College Hospital

Enrollment

30 participants

Start Date

Oct 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study was to investigate the value of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR) PET tracer, in the diagnosis of high WHO grade glioma and prediction the grade of glioma using positron-emission tomography/computed tomography (PET/CT).


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria2

  • suspected or confirmed untreated glioma patients
  • signed written consent.

Exclusion Criteria5

  • pregnancy
  • breastfeeding
  • known allergy against Pentixafor
  • any medical condition that in the opinion of the investigator,may
  • significantly interfere with study compliance

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68Ga-RM26

Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.


Locations(1)

Chinese Academy of Medical Science & Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06412952


Related Trials